Table 2.
Prevalence and AORs of Self-Reported Ongoing Symptoms Among Respondents Who Reported Testing Positive for SARS-CoV-2 Stratified by Race/Ethnicity, Weighted
| Number and type of symptom among respondents with a positive SARS-CoV-2 test | Non-Hispanic White n (%) [95% CI] |
Non-Hispanic Black/African American n (%) [95% CI] |
Hispanic n (%) [95% CI] |
Non-Hispanic othera n (%) [95% CI] |
|---|---|---|---|---|
| One or more ongoing symptomb | 402 (53.7%) [50.1%, 57.5%] |
48 (53.5%) [43.5%, 64.6%] |
159 (67.2%) [61.2%, 73.3%] |
50 (54.8%) [44.9%, 65.9%] |
| AORc [95% CI] | ref | 1.13 [0.70, 1.83] | 1.79 [1.27, 2.53] | 1.50 [0.92, 2.46] |
| Two or more ongoing symptomsb | 263 (35.2%) [31.6%, 38.7%] |
32 (35.3%) [26.4%, 46.2%] |
122 (51.4%) [45.1%, 58.2%] |
31 (33.8%) [25.0%, 44.5%] |
| AORc [95% CI] | ref | 1.16 [0.69, 1.92] | 2.03 [1.45, 2.86] | 1.39 [0.82, 2.33] |
| Respiratory/cardiac conditionsd | 221 (29.5%) [26.3%, 32.9%] |
30 (33.0%) [24.2%, 43.6%] |
88 (36.9%) [30.9%, 43.4%] |
25 (27.3%) [18.5%, 36.5%] |
| AORc [95% CI] | ref | 1.50 [0.89, 2.48] | 1.47 [1.03, 2.07] | 1.24 [0.71, 2.11] |
| Gastrointestinal conditionse | 68 (9.0%) [7.2%, 11.1%] |
11 (11.7%) [6.1%, 18.5%] |
27 (11.5%) [7.7%, 15.3%] |
14 (15.3%) [8.7%, 23.4%] |
| AORc [95% CI] | ref | 1.78 [0.73, 3.95] | 1.42 [0.77, 2.56] | 4.06 [1.78, 8.89] |
| Neurological conditionsf | 264 (35.2%) [31.8%, 38.8%] |
34 (37.8%) [27.8%, 48.1%] |
113 (47.5%) [41.2%, 54.2%] |
29 (32.1%) [23.2%, 42.5%] |
| AORc [95% CI] | ref | 1.24 [0.74, 2.04] | 1.77 [1.26, 2.48] | 1.22 [0.72, 2.05] |
| Other ongoing symptomsg | 280 (37.3%) [33.9%, 41.0%] |
35 (38.6%) [28.6%, 48.9%] |
116 (48.8%) [42.4%, 55.5%] |
30 (32.6%) [23.8%, 43.0%] |
| AORc [95% CI] | ref | 1.12 [0.68, 1.83] | 1.53 [1.09, 2.14] | 1.13 [0.67, 1.88] |
Note: Statistical weighting was used to align the sample with U.S. population distributions, adjusting for sex, age, and education. Weights were designed to match the U.S. Census ACS proportions for these variables. Estimates that are significantly different from the non-Hispanic White respondents are bolded.
Respondents who reported a race other than non-Hispanic White or Black, including Asian, American Indian, Alaskan Native, and Hawaiian/Pacific Islander, or reported 2 or more non-Hispanic races.
Post-COVID conditions included fatigue, weakness, change in smell or taste, headache, cough, joint/muscle pain, change in mood, brain fog, diarrhea, shortness of breath/breathlessness, chest pain/pressure, fever or chills, sore throat, nausea/vomiting, stomach pain, problems in sleeping, postexertional malaise, and palpitations.
Adjusted for age, sex, highest education, marital status, past year or current self-reported health conditions, and receipt of vaccination.
Respiratory/cardiac conditions include cough, chest pain, heart palpitations, sore throat, and shortness of breath.
Gastrointestinal conditions include diarrhea, stomach pain, and nausea/vomiting.
Neurologic conditions include difficulty in thinking/concentrating/brain fog, headache, problems in sleeping, change in smell or taste, and change in mood.
Other ongoing symptoms include tiredness or fatigue, postexertional malaise, fever, joint or muscle pain, and hair loss.
ACS, American Community Survey.